IBL News

The number of patients of nonalcoholic fatty liver disease, NAFLD has been increasing recently. It is critically important for distinguishing nonalcoholic steatohepatitis, NASH from NAFLD patients in clinical practice.

A liver biopsy –proven histological examination is mainly applied for NASH diagnosis in current practice, however, non-invasiveness and reliable biomarker for the diagnosis is desired from the point of view of patient burden.

Sentences above were referred to the article “A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.” Kamada Y et al. Hepatology. 2015 Jul 21.

The development of a novel non-invasiveness diagnostic method using 2 types of glycobiomarkers (fucosylated haptoglobin (Fuc-Hpt) and Mac-2 binding protein (Mac2bp)) is reported in this article. The data displayed above was provided by Professor. Eiji Miyoshi at Department of Molecular Biochemistry and Clinical Investigation, Osaka University, Graduate School of Medicine, Osaka, Japan.

It was confirmed that serum Mac2bp is effective for diagnosis of liver fibrosis severity and serum Fuc-Hpt is useful for prediction of ballooning hepatocytes for 124 patients who were diagnosed as NAFLD conducted using by a liver biopsy in this study.

In additional, it was proven that combination of these two types of glycobiomarkers brings the highly performed output in NASH diagnosis. As the result of with the results of ROC analysis, area under the ROC curve (AUROC), sensitivity, and specificity was 0.854, 81.1%, and 79.3%, respectively.

Furthermore, prediction model of NASH diagnosis was developed using a logistic regression analysis and promising results such as AUROC: 0.844, sensitivity: 71.4% and specificity: 82.3% were obtained from 382 patients group who were diagnosed as NAFLD conducted by a liver biopsy in this studies.

From these results, the combination of Fuc-Hpt and Mac2bp in serum makes it possible to distinguish NASH patients from the group of NAFLD patients and this non-invasiveness diagnostic method using two types of glycol-biomarkers is expected to become a novel NASH diagnostic tool as an alternative option of a liver biopsy.

Our product #27362 Human Mac-2 binding protein (Mac-2bp) Assay Kit – IBL is used in this study.

Please click the following link for the original article.
A novel noninvasive diagnostic method for nonalcoholicsteatohepatitis using two glycobiomarkers.
Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Mori K, Tanaka S, Yamada M, Akita M, Mizutani K, Fujii H, Yamamoto A, Takamatsu S, Yoshida Y, Itoh Y, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E.
Hepatology. 2015 Jul 21. doi: 10.1002/hep.28002. PMID:26199205

Please feel free to contact us if you have any question.

Sales Support
Diagnostic & Research Reagents Division
TEL: +81 (274) 50 8666
Email: do-ibl@ibl-japan.co.jp